Stock Events

Stock Events

Astellas Pharma 

$18.05
468
+$1.9+11.76% Today

Statistics

Day High
16.15
Day Low
16.15
52W High
17.39
52W Low
8.4
Volume
100
Avg. Volume
1,872
Mkt Cap
32.66B
P/E Ratio
24.6
Dividend Yield
1.52%
Dividend
0.27

Upcoming

30
SEP
Dividend Ex
Estimated
 
1
DEC
Dividend Payment
Estimated
 
31
MAR 27
Dividend Ex
Estimated
 
30
SEP 27
Dividend Ex
Estimated
 
1
DEC 27
Dividend Payment
Estimated
 

Dividends

1.52%Dividend Yield
Mar 26
$0.25
Dec 25
$0.26
Jun 25
$0.25
Dec 24
$0.26
Jun 24
$0.23
10Y Growth
5.04%
5Y Growth
4.14%
3Y Growth
3.32%
1Y Growth
-0.7%

Earnings

23AprExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.35
-0.11
0.12
0.36
Expected EPS
0.174318073146
Actual EPS
N/A

Financials

15.02%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
17.17BRevenue
2.58BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALPMF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company that competes with Astellas in various therapeutic areas, including oncology and urology.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is a direct competitor in the pharmaceutical industry, particularly in the oncology sector where both companies have significant investments.
Novartis
NVS
Mkt Cap237.61B
Novartis competes with Astellas in multiple areas, including research and development in innovative medicines and treatments.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes across a broad range of therapeutic areas against Astellas.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline competes with Astellas in the pharmaceutical and healthcare sector, including areas like immunology.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the biopharmaceutical field, particularly in areas like oncology, where Astellas also focuses.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is a competitor in the global pharmaceutical market, especially in cancer treatment, a key focus for Astellas.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is involved in various therapeutic areas competing with Astellas, including oncology, cardiovascular, and respiratory diseases.
Roche
RHHBY
Mkt Cap258.9B
Roche, through its pharmaceuticals division, competes with Astellas, especially in oncology and personalized healthcare.
Sanofi
SNY
Mkt Cap124.45B
Sanofi competes with Astellas in areas such as immunology and oncology, with both companies striving for innovation in healthcare.

About

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD); EVRENZO, a treatment for anemia associated with chronic kidney disease (CKD); Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressants. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. It offer its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Show more...
CEO
Mr. Naoki Okamura BSc
Employees
14754
Country
JP
ISIN
JP3942400007

Listings

MX
MX
4503N.MX
TSE
JP
4503.TSE
OTC Link
US
ALPMY
OTC Link
US
ALPMF

0 Comments

Share your thoughts

FAQ

What is Astellas Pharma stock price today?▼
The current price of ALPMF is $18.05 USD — it has increased by +11.76% in the past 24 hours. Watch Astellas Pharma stock price performance more closely on the chart.
What is Astellas Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Astellas Pharma stocks are traded under the ticker ALPMF.
Is Astellas Pharma stock price growing?▼
ALPMF stock has risen by +15.71% compared to the previous week, the month change is a +9.06% rise, over the last year Astellas Pharma has showed a +83.25% increase.
What is Astellas Pharma market cap?▼
Today Astellas Pharma has the market capitalization of 32.66B
When is the next Astellas Pharma earnings date?▼
Astellas Pharma is going to release the next earnings report on April 23, 2026.
What were Astellas Pharma earnings last quarter?▼
ALPMF earnings for the last quarter are 0.36 USD per share, whereas the estimation was 0.29 USD resulting in a +22.02% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Astellas Pharma revenue for the last year?▼
Astellas Pharma revenue for the last year amounts to 17.17B USD.
What is Astellas Pharma net income for the last year?▼
ALPMF net income for the last year is 2.58B USD.
Does Astellas Pharma pay dividends?▼
Yes, ALPMF dividends are paid semi-annual. The last dividend per share was 0.25 USD. As of today, Dividend Yield (FWD)% is 1.52%.
How many employees does Astellas Pharma have?▼
As of April 01, 2026, the company has 14,754 employees.
In which sector is Astellas Pharma located?▼
Astellas Pharma operates in the Health Care sector.
When did Astellas Pharma complete a stock split?▼
The last stock split for Astellas Pharma was on March 27, 2014 with a ratio of 5:1.
Where is Astellas Pharma headquartered?▼
Astellas Pharma is headquartered in Chuo, JP.